bond8k-apr62010.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
April 6, 2010

BOND LABORATORIES, INC.
 
     
Nevada
333-137170
20-3464383
(State or Other Jurisdiction of
Incorporation or Organization)
(Commission File Number )
(I.R.S. Employer
Identification No.)
 
11011 Q Street, Suite 106A, Omaha, NE
68137
(Address of principal executive offices)
(Zip Code)
 
Registrant’s telephone number, including area code: 402-333-5260
(Name, address, including zip code, and telephone number, including area code, of agent for service of process)
 
NOT APPLICABLE
(Former Name or Former Address, if Changes Since Last Report)

 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
As used in this report,  the terms "we",  "us",  "our",  "our company," or "the Corporation" refers to Bond Laboratories, Inc., a Nevada corporation.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Our disclosure and analysis in this Current Report on Form 8-K contains some forward-looking statements. Certain of the matters discussed concerning our operations, cash flows, financial position, economic performance and financial condition, and the effect of economic conditions include forward-looking statements.

Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates" and similar expressions are forward-looking statements. Although we believe that these statements are based upon reasonable assumptions, including projections of orders, sales, operating margins, earnings, cash flow, research and development costs, working capital, capital expenditures and other projections, they are subject to several risks and uncertainties.

Investors are cautioned that our forward-looking statements are not guarantees of future performance and the actual results or developments may differ materially from the expectations expressed in the forward-looking statements.

As for the forward-looking statements that relate to future financial results and other projections, actual results will be different due to the inherent uncertainty of estimates, forecasts and projections may be better or worse than projected. Given these uncertainties, you should not place any reliance on these forward-looking statements. These forward-looking statements also represent our estimates and assumptions only as of the date that they were made. We expressly disclaim a duty to provide updates to these forward-looking statements, and the estimates and assumptions associated with them, after the date of this filing to reflect events or changes in circumstances or changes in expectations or the occurrence of anticipated events. You are advised, however, to consult any additional disclosures we make in our reports on Form 10-K, Form 10-Q, Form 8-K, or their successors.

The Company's press release with respect to the above is attached hereto as Exhibit 99.1.
 
 
Item 2.02   Results of Operation and Financial Condition
 
This Current Report on Form 8-K is being furnished to disclose the press release issued by the Company on April 6, 2010.  The following information is being provided under Item 2.02 Disclosure of Results of Operations and Financial Condition:
 
On April 6, 2010, Bond Laboratories, Inc. issued a press release reporting that total revenue for the fiscal year ended December 31, 2009 increased to $8,734,000, as compared to $2,530,000 for the fiscal year ended December 31, 2008. Sales for the quarter ended December 31, 2009 were $1,773,000, as compared to $1,031,000 from continuing operations for the quarter ended December 31, 2008.
 
A copy of the press release is furnished as exhibit 99.1 of this report.

 
 
 
 
Item 9.01
 Financial Statements and Exhibits.
 
(d)  Exhibits
 
     Exhibit 99.1   Press release of Bond Laboratories, Inc., dated April 6, 2010.
 
    
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

April 12, 2010

Bond Laboratories, Inc.

 
By:  
/s/ John S. Wilson
 
John S. Wilson
 
Chief Executive Officer, Director